Status:
COMPLETED
The Use of Statins for Myocardial Death Prevention
Lead Sponsor:
Rambam Health Care Campus
Collaborating Sponsors:
Pfizer
Conditions:
Myocardial Infarction
Eligibility:
All Genders
30-90 years
Phase:
PHASE4
Brief Summary
The administration of high dose HMG-CoA reductase inhibitors (Statins) to patients with acute ST-elevation MI (hypoxia/ischemia) who are treated with primary PCI (reoxygenation/ reperfusion) will prot...
Eligibility Criteria
Inclusion
- 1\. Patients suffering from acute ST elevation resulting from myocardial infarction, Killip Classification 1 and 2 will be included at-random to either group. Included subjects should be able to give their informed consent to participate in this study.
Exclusion
- The impossibility to give the required informed consent.
- Known allergy to Atorvastatin.
- Base line serum creatinine of 1.4 mg/dL.
- Killip Classification 3 and 4.
- Persisting vomiting.
- History of previous liver disease.
- History of previous muscle disease or rabdomyolisis.
- Treated already with high dose atorvastatin
- Non Compliance.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00772564
Start Date
August 1 2008
End Date
August 1 2010
Last Update
May 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam Health Care Campus
Haifa, Haifa District, Israel, 31096